Alamar Biosciences, Inc. (NASDAQ:ALMR) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Alamar Biosciences, Inc. (NASDAQ:ALMR) have been given an average rating of “Moderate Buy” by the six research firms that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $30.00.

Several research firms recently issued reports on ALMR. Leerink Partners began coverage on Alamar Biosciences in a research note on Tuesday, May 12th. They issued an “outperform” rating and a $35.00 target price on the stock. JPMorgan Chase & Co. initiated coverage on shares of Alamar Biosciences in a report on Tuesday, May 12th. They issued an “overweight” rating and a $30.00 price objective for the company. TD Cowen initiated coverage on shares of Alamar Biosciences in a report on Tuesday, May 12th. They issued a “buy” rating and a $30.00 price objective for the company. Wall Street Zen upgraded shares of Alamar Biosciences to a “hold” rating in a report on Saturday, April 25th. Finally, Stifel Nicolaus started coverage on shares of Alamar Biosciences in a research report on Tuesday, May 12th. They set a “buy” rating and a $28.00 price target on the stock.

Alamar Biosciences Stock Performance

ALMR stock opened at $20.54 on Friday. Alamar Biosciences has a one year low of $18.84 and a one year high of $27.20.

Alamar Biosciences (NASDAQ:ALMR) last announced its quarterly earnings data on Friday, May 8th. The company reported ($1.74) earnings per share (EPS) for the quarter. The firm had revenue of $26.04 million during the quarter.

Insider Activity at Alamar Biosciences

In other news, Director Nicholas Naclerio acquired 235,294 shares of the business’s stock in a transaction on Monday, April 20th. The shares were acquired at an average cost of $17.00 per share, with a total value of $3,999,998.00. Following the transaction, the director owned 507,076 shares in the company, valued at $8,620,292. The trade was a 86.57% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Innovation Fund Gp Illumina II purchased 235,294 shares of the company’s stock in a transaction dated Monday, April 20th. The stock was bought at an average cost of $17.00 per share, for a total transaction of $3,999,998.00. Following the completion of the transaction, the insider owned 507,076 shares in the company, valued at approximately $8,620,292. This represents a 86.57% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Alamar Biosciences Company Profile

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.